Kura Oncology Launches $50M-Backed Diabetes Venture for Oral Menin Inhibitor

Caspian Therapeutics and Kura Oncology (KURA) presented a development plan for KO-7246, an oral menin inhibitor for diabetes. Preclinical data showed potential to increase insulin production and improve glucose control. Caspian aims to start Phase 1 trials. KURA is down 4.14% at $9.94.

Caspian Therapeutics and Kura Oncology (KURA) will discuss the development strategy for KO-7246, an oral menin inhibitor for diabetes, in a webcast. Preclinical findings showed improved glucose control and beta cell expansion in animal models. Caspian plans to conduct a Phase 1 clinical trial to assess safety and insulin production. Kura owns half of Caspian and retains research collaboration rights.

JPMorgan initiated coverage of Kura Oncology with an overweight rating and a $30 price target, citing strong sales of its approved cancer drug Komzifti and potential of its experimental drug darlifarnib. Komzifti's revenue grew from $2.1M to $9.1M in Q2 2026, with estimated peak sales of $1.5B. Shares were up 1% on Thursday.

JPMorgan initiated Kura Oncology (KURA) with an overweight rating and $30 price target, citing strong potential in its oncology drugs. The company's Q2 2026 earnings beat expectations, with revenue of $20.87M. Insider purchases and positive analyst revisions also supported the stock, which has gained 28% over six months.

Caspian Therapeutics and Kura Oncology presented preclinical data on KO-7246, a menin inhibitor, showing potential for diabetes treatment. KO-7246 regenerated β-cell mass and controlled glycemic levels in Type 1 and Type 2 diabetes models. Caspian aims to develop KO-7246 as a best-in-class therapy, with an investor event scheduled for October 13, 2026.

Kura Oncology (KURA) launched Caspian Therapeutics, a spin-off focused on menin inhibition therapies for diabetes and cardiometabolic diseases. Kura retains 50% ownership. The company's P/S ratio is 14.3x, above its historical median of 10.6x, reflecting growth expectations despite unprofitability. Insider activity shows net selling, while guru investors have mixed positions.